Franziska W.
- Country
- Germany
- Department
- II. Medizinische Klinik und Poliklinik
Research Overview
- Evaluation of Adverse Events, Pharmacokinetics, and Disease Activity of Oral ABBV-101 in Adult Patients with Select B-Cell Malignancies
- Phase 1/2 Study of SNDX-5613 in Relapsed/Refractory Acute Leukemias with MLL/KMT2A Rearrangement or NPM1 Mutation
- Evaluation of Safety and Preliminary Efficacy of IL12-L19L19 in Patients with Advanced or Metastatic Carcinomas Post-Immune Checkpoint Blockade Therapy
Data & Insights
Has run more than one trial at 5 of 41 partner sites.
Specializations
Hematologic Oncology
This investigator specializes in the treatment of acute myeloid leukemia (AML), with particular focus on newly diagnosed cases featuring specific genetic risk profiles.
- Intermediate and adverse-risk AML genetics
- AML with myelodysplasia-related changes
- Therapy-related AML
The investigator's work encompasses evaluation of innovative therapeutic approaches in accordance with World Health Organization (WHO) classification standards.
Genetic Risk Assessment
The investigator focuses on risk stratification in hematologic malignancies, particularly utilizing the European LeukemiaNet (ELN) criteria for genetic risk assessment.
- Genetic profiling in AML
- Risk-adapted treatment strategies
- Molecular classification systems
Their expertise includes comprehensive genetic analysis for treatment planning in newly diagnosed patients.
Treatment Innovation
The investigator evaluates intensive chemotherapy approaches in hematologic malignancies, comparing standard protocols with novel therapeutic formulations.
- Advanced chemotherapy protocols
- Survival outcome assessment
- De novo AML treatment
Their research explores therapeutic innovations for improving patient outcomes in challenging genetic subtypes of AML.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.